Genomic testing for breast cancer in the neoadjuvant setting

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the value of genomic tests for identifying breast cancer patients who are likely to benefit from neoadjuvant chemotherapy. Genomic testing may be beneficial for patients with intermediate-risk factors, as determined by classic clinicopathological tools, of tumour progression during therapy.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:
Color/Sound:

2015
01:30
Color/Sound

Comments are closed.